Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ed Reznik

Showing results (71-80 of 105) with videos related to

Pageof 11
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 4, 2021
Comprehensive Molecular Characterization and Response to Therapy in Fumarate Hydratase-Deficient Renal Cell CarcinomaJack P Gleeson, Ines Nikolovski, Renzo Dinatale, et al.
European Urology Focus|September 28, 2017
Characterization and Impact of TERT Promoter Region Mutations on Clinical Outcome in Renal Cell CarcinomaJozefina Casuscelli, Maria F Becerra, Brandon J Manley, et al.
European Urology Focus|December 10, 2019
Putative Drivers of Aggressiveness in TCEB1-mutant Renal Cell Carcinoma: An Emerging Entity with Variable Clinical CourseRenzo G DiNatale, Alexander N Gorelick, Vladimir Makarov, et al.
Biorxiv : the Preprint Server for Biology|March 30, 2023
Tumour mitochondrial DNA mutations drive aerobic glycolysis to enhance checkpoint blockadeMahnoor Mahmood, Eric Minwei Liu, Amy L Shergold, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 15, 2021
Prevalence and Landscape of Actionable Genomic Alterations in Renal Cell CarcinomaKyrollis Attalla, Renzo G DiNatale, Phillip M Rappold, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 30, 2020
Comprehensive Genomic Analysis of Translocation Renal Cell Carcinoma Reveals Copy-Number Variations as Drivers of Disease ProgressionJulian Marcon, Renzo G DiNatale, Alejandro Sanchez, et al.
Molecular Cancer Research : MCR|May 27, 2021
High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and PembrolizumabChung-Han Lee, Renzo G DiNatale, Diego Chowell, et al.
Science (New York, N.Y.)|November 9, 2019
Double <i>PIK3CA</i> mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitorsNeil Vasan, Pedram Razavi, Jared L Johnson, et al.
Nature Cancer|January 29, 2024
Mitochondrial DNA mutations drive aerobic glycolysis to enhance checkpoint blockade response in melanomaMahnoor Mahmood, Eric Minwei Liu, Amy L Shergold, et al.
European Urology|November 5, 2025
MLH1 Mismatch Repair Deficiency Predicts Exceptional Response to Immune Checkpoint Inhibition in Clear-cell Renal Cell CarcinomaMark T Dawidek, Lina Posada Calderon, Parantu K Shah, et al.
Pageof 11

Showing results (71-80 of 105) with videos related to

Sort By:
Pageof 11
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 4, 2021
Comprehensive Molecular Characterization and Response to Therapy in Fumarate Hydratase-Deficient Renal Cell CarcinomaJack P Gleeson, Ines Nikolovski, Renzo Dinatale, et al.
European Urology Focus|September 28, 2017
Characterization and Impact of TERT Promoter Region Mutations on Clinical Outcome in Renal Cell CarcinomaJozefina Casuscelli, Maria F Becerra, Brandon J Manley, et al.
European Urology Focus|December 10, 2019
Putative Drivers of Aggressiveness in TCEB1-mutant Renal Cell Carcinoma: An Emerging Entity with Variable Clinical CourseRenzo G DiNatale, Alexander N Gorelick, Vladimir Makarov, et al.
Biorxiv : the Preprint Server for Biology|March 30, 2023
Tumour mitochondrial DNA mutations drive aerobic glycolysis to enhance checkpoint blockadeMahnoor Mahmood, Eric Minwei Liu, Amy L Shergold, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 15, 2021
Prevalence and Landscape of Actionable Genomic Alterations in Renal Cell CarcinomaKyrollis Attalla, Renzo G DiNatale, Phillip M Rappold, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 30, 2020
Comprehensive Genomic Analysis of Translocation Renal Cell Carcinoma Reveals Copy-Number Variations as Drivers of Disease ProgressionJulian Marcon, Renzo G DiNatale, Alejandro Sanchez, et al.
Molecular Cancer Research : MCR|May 27, 2021
High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and PembrolizumabChung-Han Lee, Renzo G DiNatale, Diego Chowell, et al.
Science (New York, N.Y.)|November 9, 2019
Double <i>PIK3CA</i> mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitorsNeil Vasan, Pedram Razavi, Jared L Johnson, et al.
Nature Cancer|January 29, 2024
Mitochondrial DNA mutations drive aerobic glycolysis to enhance checkpoint blockade response in melanomaMahnoor Mahmood, Eric Minwei Liu, Amy L Shergold, et al.
European Urology|November 5, 2025
MLH1 Mismatch Repair Deficiency Predicts Exceptional Response to Immune Checkpoint Inhibition in Clear-cell Renal Cell CarcinomaMark T Dawidek, Lina Posada Calderon, Parantu K Shah, et al.
Pageof 11